Skip to main content

Everything we do at Amylyx is centered around those living with neurodegenerative diseases. We're working to discover and develop new treatments with the potential to give people more quality time with the ones they love.

Health Canada Approves ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) for the Treatment of ALS

Amylyx is proud to announce that Health Canada has approved ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death in people living with ALS, either as a stand-alone therapy or when added to existing treatments.

EMA Validation of MAA for AMX0035 for the Treatment of ALS

Amylyx is proud to announce that the European Medicines Agency (EMA) has validated our Marketing Authorisation Application (MAA) for AMX0035 for the treatment of ALS and is now reviewing our MAA.

In pursuit of more

Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn about our unique culture, approach to clinical trials for AMX0035, and more.

Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn about our unique culture, approach to clinical trials for AMX0035, and more.

Latest News